International

Europe

Trinity has been working on key European challenges for over 25 years. We have completed 1,200 European projects in the last five years.

Home / International / Europe

Trinity has been working on European challenges since the inception of our firm. We understand the European market and can offer strategic support to both our global and regional European clients. Our European offices are in London and Munich.

From Strategy to Execution: Our Team Provides Comprehensive Support to Clients Facing Commercialization Challenges in Europe and Beyond

We work closely with other specialized teams to ensure that our clients receive the best possible expertise and solutions.

Forecasting

Corporate Strategy

Brand & Marketing Excellence

Launch Excellence

Dynamic Market Intelligence

Evidence Strategy (HEOR)

Commercial Analytics

PMR & Patient Centricity

Value, Access & Pricing

Explore Trinity’s Expertise

Questions We Can Help You Answer
What are the key commercial and go-to-market considerations for Europe?
- How do we sequence launch in the EU? Are there any markets we should not target at all?
- How do we prepare for launch in each country?
  - How much time is needed and which resources?
- What is the CHMP evaluation process and how can we optimize the EC approval to launch process?
- What are some of the key access considerations in each European market?
- What are the generic adoption levels and how do they vary by country?
How do we enter and be successful in the European markets?
- What are some of the business development and outlicensing considerations?
- What drivers and barriers can we uncover for each market specifically?
- How can identify and fulfill key unmet needs
What local innovation and business development opportunities should we pursue?
- What specific healthcare trends shape the market in each country and how can we explore them?
- How do stakeholders (physicians, payers, patients) perceive these innovations/developments)?
Unique regional capabilities
- Multilingual experts that are fluent in local languages (French, German, Italian, Spanish, Portuguese, etc.) to ensure optimal execution of research programs
- Local offices in Munich and London
- Extensive network of stakeholder types, including KOLs, providers, regulatory experts, payers and patients
- Ability to conduct market research in different formats (in-person, telephone, video platform, central facility, web survey)

Latest Intelligence About Europe

Blog

Learnings to Kick-Start 2025: Joint Clinical Assessments and Health Technology Assessments

One trend Trinity Life Sciences has observed and that was reinforced by stakeholders at ISPOR EU is the importance of evidence in healthcare decision-making. This trend was highlighted particularly in the context of joint clinical assessments (JCA) and health technology assessments (HTA). Trinity presented 11 posters at ISPOR EU, 6 of which focused on HTA and/or […]

Briefs

Global Dossiers in the Joint Clinical Assessment Era: Impacts and Implications

Joint clinical assessment (JCA) is a European Union (EU) initiative intended to improve patient access to health technologies in Europe through a harmonized clinical health technology assessment (HTA) process. From January 2025, all new oncology medicines and advanced therapy medicinal products will go through the JCA process, followed by all orphan medicinal products from 2028 […]

Blog

Rise with the Waves: Italy – AIFA Restructuring and Budget Reforms – Stepping into a New (Uncertain) Future?

Executive Summary The Italian Medicines Agency (AIFA) underwent transformative changes on January 30, 2024, following a much-anticipated reorganization. AIFA’s restructuring has already faced challenges, with the recent resignation of the newly created Scientific and Economic Commission’s (CSE) chairman followed by the appointment of a new acting chairman, highlighting the need for a stable and collaborative […]

View All Thought Leadership About Europe